Emerging World Pharma Inc. Strategic Partner African Global Pharma Corp. Approval From Food & Drugs Board Ghana for Anti-Mala...
28 11월 2012 - 10:30PM
Marketwired
Emerging World Pharma Inc. (PINKSHEETS: EWPI)
strategic partner African Global Pharma Corp. (AGP) has informed us
that the Food and Drugs Board of Ghana approval of the
anti-malarial pharmaceutical Gloderp
® is in
the final stages of the registration process with the company
anticipating full approval before this quarter end
. The Food and Drugs Board of Ghana is a Ghanaian
government agency responsible for the inspection, certification and
proper distribution of foods and food products and drugs in Ghana.
There remains an ongoing demand for anti-malarial medicines in
Ghana and surrounding African countries that is readily made
available at affordable prices.
Upon approval African Global Pharma GH would be the only
manufacturer of Golderp® in capsule form in Ghana. This would allow
AGP to readily manufacture and distribute the anti-malarial
medicine in an affordable and timely manner throughout Ghana and
other West African countries. It will be produced in (AGP) Sunyani,
Ghana manufacturing facility.
Gloderp® is used for the treatment of
uncomplicated malaria caused by falciparum, vivax and or malariae.
Each capsule will contain Dihydroartemisinin 40mg and Piperaquine
Phosphate 320mg.
About African Global Pharma, Ghana African
Global Pharma (Ghana) Limited is an affiliated company of African
Global Pharma Corp. of Canada with business partnership with the
Catholic Diocese of Sunyani to distribute all our manufactured
drugs to the Catholic Mission Hospitals. African Global Pharma's
production facility in Sunyani, Ghana was fully rehabilitated and
built by African Global Pharma Corp, Canada. The plant and its
operations are headquartered in Sunyani at the Diocesan Bldg.
For more on AGP click here
http://www.globalpharmacorp.ca/african-gp-ghana.html
About Emerging World Pharma Inc. Emerging
World Pharma Inc. is an investor in generic based pharmaceutical
companies manufacturing within developing nations.
The company focuses its investments on generic pharmaceutical
companies that have contracts with three major buyer groups;
church, government and wholesalers. Market research shows that
these branches are the most secure, protected and reputable for the
distribution of medicines.
For more on Emerging World Pharma Inc. click here
http://www.emergingpharma.com/
Forward Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Statements in this release that are forward-looking
statements are based on current expectations and assumptions that
are subject to known and unknown risks, uncertainties, or other
factors which may cause actual results, performance, or
achievements of the company to be materially different from any
future results, performance, or achievements expressed or implied
by such forward-looking statements. Actual results could differ
materially because of factors such as the effect of general
economic and market conditions, entry into markets with vigorous
competition, market acceptance of new products and services,
continued acceptance of existing products and services,
technological shifts, and delays in product development and related
product release schedules, any of which may cause revenues and
income to fall short of anticipated levels. All information in this
release is as of the date of this release. The company undertakes
no duty to update any forward-looking statement to conform the
statement to actual results or changes in the company's
expectations.
Contact: Joel Everret Emerging World Pharma Inc. Investor
Relations Division 703-646-2633 Email: info@emergingpharma.com
Website: http://www.emergingpharma.com/
Emerging World Pharma (CE) (USOTC:EWPI)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Emerging World Pharma (CE) (USOTC:EWPI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024